DOCSLIB.ORG

Antipsychotic Class Review

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Antipsychotic Class Review IOWA MEDICAID P&T COMMITTEE THERAPEUTIC CLASS REVIEW AUGUST 10, 2012 ANTIPSYCHOTICS CLASS REVIEW [Literature Review search through July 16, 2012] [Last Review Update: August 9, 2012] Property of IME and may not be reproduced without permission. Requests for permission to use this material should be addressed to: [email protected]. Property of IME and may not be reproduced without permission. Antipsychotics‐2 SYNOPSIS Antipsychotics are also known as neuroleptic drugs, which comes from the Greek meaning "taking hold of one’s nerves". Antipsychotics are used to treat numerous psychiatric diagnoses including schizophrenia, bipolar disorder, aggression and irritability associated with autism and as augmentation agents for patients with major depressive disorder who fail to respond to antidepressant monotherapy. The first generation antipsychotics (FGAs), or the typical antipsychotics, have been in existence since the 1950s, while second generation antipsychotics, also known as the atypical antipsychotics (AAPs), have been available since the 1990s. The atypical antipsychotics are now considered 1st line treatment for schizophrenia and are one of the most widely prescribed drug classes. Schizophrenia affects approximately 1.1% of the U.S. adult population. Schizophrenia is a severe, progressive, chronic brain disorder, with symptoms falling into one of three categories. The categories include: (1) positive symptoms, which are unusual thoughts or perceptions (delusions and hallucinations respectively); (2) negative symptoms, which are a loss or decrease in the ability to initiate plans, speak or find pleasure in everyday life; and (3) cognitive deficits.30 Bipolar disorder, also known as manic‐depressive illness, is also a chronic brain disorder that's characterized as a mood disorder with periods of depression and mania. Bipolar disorder can cause a dramatic shift in mood, energy, and a person’s ability to function in numerous domains. These severe symptoms can lead to difficulties in leading a productive life if not properly treated and managed. There are currently 5.7 millions adults in the U. S. that are diagnosed with bipolar disorder, which is approximately 2.6% of the population. Individuals with bipolar disorder have increased rates of substance abuse, divorce, unemployment, and arrest rates. Bipolar disorder typically develops in late adolescence or early adulthood.29 Major depressive disorder has a lifetime prevalence of 16 % in the United States. First line antidepressant treatment is often ineffective at relieving symptoms. Augmentation of antidepressants is a commonly employed strategy and certain atypical antipsychotics have been demonstrated to be efficacious. Clozapine was first discovered in the 1950's, but was not used in clinical practice in the United States until 1990. Clozapine was found to be most effective for treatment resistant schizophrenia; however, associated adverse events limited its use. This led to the advent of newer atypicals with more tolerable side effect profiles compared with clozapine. Risperidone (Risperdal®) was the first of the newer atypicals, followed by olanzapine (Zyprexa®) and then quetiapine (Seroquel®) that were developed in the 1990's. Ziprasidone (Geodon®) and aripiprazole (Abilify®) became available in the early 2000’s. Paliperidone (Invega®) became available in 2006, while iloperidone (Fanapt®) and asenapine (Saphris®) became available in 2009. Most recently, the newest product that has been approved by the FDA is lurasidone (Latuda®). The frequency and severity of adverse events and drug‐drug interactions helps to differentiate the products from the earlier first generation antipsychotics such as haloperidol or perphenazine, with the atypicals. The oral atypical antipsychotics included in this therapeutic class review include: aripiprazole (Abilify®), asenapine (Saphris®), clozapine (Clozaril®, Fazaclo®), iloperidone (Fanapt®), lurasidone (Latuda®), olanzapine (Zyprexa®), olanzapine/fluoxetine (Symbyax®), paliperidone (Invega®), quetiapine (Seroquel®), quetiapine XR (Seroquel XR®), risperidone (Risperdal®), and ziprasidone (Geodon®). Property of IME and may not be reproduced without permission. Antipsychotics‐3 The injectable atypicals included in this therapeutic class review include: aripiprazole (Abilify®), olanzapine (Zyprexa® IntraMuscular, Zyprexa® Relprevv), paliperidone (Invega® Sustenna), risperidone (Risperdal® Consta), and ziprasidone (Geodon®). The oral typical antipsychotics included in this therapeutic class review include: chlorpromazine, fluphenazine, haloperidol (Haldol®), loxapine (Loxitane®), perphenazine, perphenazine/amitriptyline, pimozide (Orap®), thioridazine, thiothixene (Navane®), and trifluoperazine. Molindone (Moban®) is a typical antipsychotic used for schizophrenia. While there is no CMS term date, the manufacturer has recently discontinued this product and thus it will not be included in the review. The injectable typical antipsychotics included in this therapeutic class review include: chlorpromazine, fluphenazine decanoate, haloperidol (Haldol®), and haloperidol decanoate (Haldol® decanoate). Property of IME and may not be reproduced without permission. Antipsychotics‐4 ATYPICAL ANTIPSYCHOTICS FDA APPROVED INDICATIONS 1‐9, 32‐34, 67, 95‐99 Please note that the indications listed in the table below are for adults aged 18 years of age or older. Adult Indications ARI ASE CLO ILO LUR OLA OLA/FLU PAL QUE QUE XR RIS ZIP Bipolar I: Acute Mania, X X X X X X X Monotherapy Bipolar I: Acute Mania, Adjunct X X X X X X to valproate or lithium Bipolar I: Depression X X X Bipolar II: Depression X X Bipolar I: Mixed, Monotherapy X X X X X X Bipolar I: Mixed, Adjunct Therapy X X X X X to valproate or lithium Bipolar Maintenance: X X Monotherapy Bipolar Maintenance: Adjunct X X X X MDD Adjunct Therapy X X Schizoaffective Disorder: X Monotherapy & Adjunct Schizophrenia X X X X X X X X X X Treatment‐resistant Depression X Treatment‐resistant Schizophrenia X Recurrent suicidal behavior X w/Schizophrenia ARI‐aripiprazole (Abilify®); ASE‐ asenapine (Saphris®); CLO‐clozapine (Clozaril®, Fazaclo®); ILO‐iloperidone (Fanapt®); LUR‐lurasidone (Latuda®); OLA‐olanzapine (Zyprexa®); OLA/FLU‐ olanzapine/fluoxetine (Symbyax®); paliperidone (Invega®); QUE‐quetiapine (Seroquel®); QUE SR‐quetiapine SR (Seroquel® XR); RIS‐ risperidone (Risperdal®); ZIP‐ziprasidone (Geodon®). The following table illustrates the current FDA approved indications for the injectables. Property of IME and may not be reproduced without permission. Antipsychotics‐5 Agitation with Drug Schizophrenia Bipolar I: Monotherapy Bipolar I: Adjunct schizophrenia/bipolar aripiprazole * X2 (Abilify®) olanzapine * X1, 3 (Zyprexa® IntraMuscular) olanzapine ** X (Zyprexa® Relprevv) paliperidone ** X (Invega® Sustenna) risperidone ** X X X (Risperdal® Consta) ziprasidone* X3 (Geodon®) 1 Bipolar I Mania 2Bipolar disorder, Manic or Mixed 3Schizophrenia *Short‐acting injectables (SAI); **Long‐acting injectables (LAI) The following table illustrates the current FDA approved indications in the pediatric population. Drug Schizophrenia Bipolar I: Acute Mania1 Bipolar I: Mixed1 Irritability associated with autism aripiprazole 13‐17 yrs 10‐17 yrs 10‐17 yrs 6‐17 yrs (Abilify®) olanzapine 13‐17 yrs 13‐17 yrs 13‐17 yrs ‐ (Zyprexa®) paliperidone 12‐17 yrs ‐ ‐ ‐ (Invega®) quetiapine 13‐17 yrs 10‐17 yrs ‐ ‐ (Seroquel®) risperidone 13‐17 yrs 10‐17 yrs 10‐17 yrs 5‐16 yrs (Risperdal®) 1 Monotherapy DOSAGE FORMS, DOSE, MANUFACTURER1‐9, 32‐34, 67, 95‐99 Currently, the only generic versions available in this therapeutic class include clozapine (Clozaril®) and risperidone (Risperdal®). Daily doses may vary within the provided dose range based upon age and indication. Property of IME and may not be reproduced without permission. Antipsychotics‐6 Drug Dosage Forms Dose Manufacturer Tablets: 2mg, 5mg, 10mg, 15mg, aripiprazole 20mg, 30mg (Abilify®) Orally Disintegrating Tablet: 10‐30mg QD Bristol‐Myers Squibb (Abilify® Disc) 10mg, 15mg Oral Solution: 1mg/ml asenapine Sublingual Tablets: 5‐10mg BID Schering‐Plough (Saphris®) 5mg, 10mg Tablets1: clozapine 25mg, 50mg, 100mg, 200mg Various generic manufacturers (Clozaril®) Orally Disintegrating Tablet: 100‐900mg divided as TID (Novartis) (Fazaclo®) 12.5mg, 25mg, 100mg, (Azur Pharma) 150mg, 200mg Tablets: iloperidone Initial dose of 1mg BID, 1mg, 2mg, 4mg, 6mg, 8mg, Vanda Pharmaceuticals (Fanapt®) target of 6‐12mg BID 10mg, 12mg lurasidone Tablets: 40‐160mg QD with food Sunovion Pharmaceuticals (Latuda®) 20mg, 40mg, 80mg (at least 350 calories) Tablets: olanzapine 2.5mg, 5mg, 7.5mg, 10mg, Various generic manufacturers (Zyprexa®) 15mg, 20mg 5‐20mg QD (Lilly) (Zyprexa® Zydis) Orally Disintegrating Tablet: 5mg, 10mg, 15mg, 20mg Capsules: olanzapine/fluoxetine 3/25mg, 6/25mg, 6/50mg, QPM dosing, max: 18/75mg Lilly (Symbyax®) 12/25mg, 12/50mg paliperidone Extended‐Release Tablets: 3‐6mg QD, max:12mg Janssen (Invega®) 1.5mg, 3mg, 6mg, 9mg Tablets: quetiapine QD to BID dosing, Various generic manufacturers 25mg, 50mg, 100mg, 200mg, (Seroquel®) max:800mg (AstraZeneca) 300mg, 400mg Extended‐Release Tablets: quetiapine XR 50mg, 150mg, 200mg, 300‐800mg QPM AstraZeneca (Seroquel® XR) 300mg, 400mg Tablets/M‐Tabs (ODT): risperidone 0.25mg, 0.5mg, 1mg, 2mg, QD to BID dosing, with Various generic manufacturers (Risperdal®) 3mg, 4mg effective dose range 4‐16mg2 ( Janssen) (Risperdal® M tab) Oral Solution: 1mg/ml Property of IME and may not be reproduced without permission. Antipsychotics‐7 Drug Dosage
Load more

Recommended publications
  • 2D6 Substrates 2D6 Inhibitors 2D6 Inducers
    Physician Guidelines: Drugs Metabolized by Cytochrome P450’s 1 2D6 Substrates Acetaminophen Captopril Dextroamphetamine Fluphenazine Methoxyphenamine Paroxetine Tacrine Ajmaline Carteolol Dextromethorphan Fluvoxamine Metoclopramide Perhexiline Tamoxifen Alprenolol Carvedilol Diazinon Galantamine Metoprolol Perphenazine Tamsulosin Amiflamine Cevimeline Dihydrocodeine Guanoxan Mexiletine Phenacetin Thioridazine Amitriptyline Chloropromazine Diltiazem Haloperidol Mianserin Phenformin Timolol Amphetamine Chlorpheniramine Diprafenone Hydrocodone Minaprine Procainamide Tolterodine Amprenavir Chlorpyrifos Dolasetron Ibogaine Mirtazapine Promethazine Tradodone Aprindine Cinnarizine Donepezil Iloperidone Nefazodone Propafenone Tramadol Aripiprazole Citalopram Doxepin Imipramine Nifedipine Propranolol Trimipramine Atomoxetine Clomipramine Encainide Indoramin Nisoldipine Quanoxan Tropisetron Benztropine Clozapine Ethylmorphine Lidocaine Norcodeine Quetiapine Venlafaxine Bisoprolol Codeine Ezlopitant Loratidine Nortriptyline Ranitidine Verapamil Brofaramine Debrisoquine Flecainide Maprotline olanzapine Remoxipride Zotepine Bufuralol Delavirdine Flunarizine Mequitazine Ondansetron Risperidone Zuclopenthixol Bunitrolol Desipramine Fluoxetine Methadone Oxycodone Sertraline Butylamphetamine Dexfenfluramine Fluperlapine Methamphetamine Parathion Sparteine 2D6 Inhibitors Ajmaline Chlorpromazine Diphenhydramine Indinavir Mibefradil Pimozide Terfenadine Amiodarone Cimetidine Doxorubicin Lasoprazole Moclobemide Quinidine Thioridazine Amitriptyline Cisapride
    [Show full text]
  • Appendix 13C: Clinical Evidence Study Characteristics Tables
    APPENDIX 13C: CLINICAL EVIDENCE STUDY CHARACTERISTICS TABLES: PHARMACOLOGICAL INTERVENTIONS Abbreviations ............................................................................................................ 3 APPENDIX 13C (I): INCLUDED STUDIES FOR INITIAL TREATMENT WITH ANTIPSYCHOTIC MEDICATION .................................. 4 ARANGO2009 .................................................................................................................................. 4 BERGER2008 .................................................................................................................................... 6 LIEBERMAN2003 ............................................................................................................................ 8 MCEVOY2007 ................................................................................................................................ 10 ROBINSON2006 ............................................................................................................................. 12 SCHOOLER2005 ............................................................................................................................ 14 SIKICH2008 .................................................................................................................................... 16 SWADI2010..................................................................................................................................... 19 VANBRUGGEN2003 ....................................................................................................................
    [Show full text]
  • The Effects of Antipsychotic Treatment on Metabolic Function: a Systematic Review and Network Meta-Analysis
    The effects of antipsychotic treatment on metabolic function: a systematic review and network meta-analysis Toby Pillinger, Robert McCutcheon, Luke Vano, Katherine Beck, Guy Hindley, Atheeshaan Arumuham, Yuya Mizuno, Sridhar Natesan, Orestis Efthimiou, Andrea Cipriani, Oliver Howes ****PROTOCOL**** Review questions 1. What is the magnitude of metabolic dysregulation (defined as alterations in fasting glucose, total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and triglyceride levels) and alterations in body weight and body mass index associated with short-term (‘acute’) antipsychotic treatment in individuals with schizophrenia? 2. Does baseline physiology (e.g. body weight) and demographics (e.g. age) of patients predict magnitude of antipsychotic-associated metabolic dysregulation? 3. Are alterations in metabolic parameters over time associated with alterations in degree of psychopathology? 1 Searches We plan to search EMBASE, PsycINFO, and MEDLINE from inception using the following terms: 1 (Acepromazine or Acetophenazine or Amisulpride or Aripiprazole or Asenapine or Benperidol or Blonanserin or Bromperidol or Butaperazine or Carpipramine or Chlorproethazine or Chlorpromazine or Chlorprothixene or Clocapramine or Clopenthixol or Clopentixol or Clothiapine or Clotiapine or Clozapine or Cyamemazine or Cyamepromazine or Dixyrazine or Droperidol or Fluanisone or Flupehenazine or Flupenthixol or Flupentixol or Fluphenazine or Fluspirilen or Fluspirilene or Haloperidol or Iloperidone
    [Show full text]
  • Revision of Precautions Asenapine Maleate, Aripiprazole, Olanzapine
    Published by Translated by Ministry of Health, Labour and Welfare Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail. Revision of Precautions Asenapine maleate, aripiprazole, olanzapine, quetiapine fumarate, clocapramine hydrochloride hydrate, chlorpromazine hydrochloride, chlorpromazine hydrochloride/promethazine hydrochloride/phenobarbital, chlorpromazine phenolphthalinate, spiperone, zotepine, timiperone, haloperidol, paliperidone, pipamperone hydrochloride, fluphenazine decanoate, fluphenazine maleate, brexpiprazole, prochlorperazine maleate, prochlorperazine mesilate, Pharmaceuticals and Medical Devices Agency Office of Safety I 3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan E-mail: [email protected] Published by Translated by Ministry of Health, Labour and Welfare Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail. propericiazine, bromperidol, perphenazine, perphenazine hydrochloride, perphenazine fendizoate, perphenazine maleate, perospirone hydrochloride hydrate, mosapramine hydrochloride, risperidone (oral drug), levomepromazine hydrochloride, levomepromazine maleate March 27, 2018 Non-proprietary name Asenapine maleate,
    [Show full text]
  • Reference 8 Huang Repurposing Psychiatric Drugs for Cancer 18
    Cancer Letters 419 (2018) 257e265 Contents lists available at ScienceDirect Cancer Letters journal homepage: www.elsevier.com/locate/canlet Mini-review Repurposing psychiatric drugs as anti-cancer agents * Jing Huang a, b, c, d, Danwei Zhao e, Zhixiong Liu a, Fangkun Liu a, a Department of Neurosurgery, Xiangya Hospital, Central South University (CSU), Changsha, China b Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China c Mental Health Institute of the Second Xiangya Hospital, Central South University, Chinese National Clinical Research Center for Mental Disorders (Xiangya), Changsha, Hunan, 410011, China d Chinese National Technology Institute on Mental Disorders, Hunan Key Laboratory of Psychiatry and Mental Health, Changsha, Hunan, 410011, China e Xiangya Medical School, Central South University, Changsha, Hunan, China article info abstract Article history: Cancer is a major public health problem and one of the leading contributors to the global disease burden. Received 10 November 2017 The high cost of development of new drugs and the increasingly severe burden of cancer globally have Received in revised form led to increased interest in the search and development of novel, affordable anti-neoplastic medications. 17 January 2018 Antipsychotic drugs have a long history of clinical use and tolerable safety; they have been used as good Accepted 19 January 2018 targets for drug repurposing. Being used for various psychiatric diseases for decades, antipsychotic drugs are now reported to have potent anti-cancer properties against a wide variety of malignancies in addition Keywords: to their antipsychotic effects. In this review, an overview of repurposing various psychiatric drugs for Antipsychotic drugs Drug repurposing cancer treatment is presented, and the putative mechanisms for the anti-neoplastic actions of these Cancer treatment antipsychotic drugs are reviewed.
    [Show full text]
  • Management of Major Depressive Disorder Clinical Practice Guidelines May 2014
    Federal Bureau of Prisons Management of Major Depressive Disorder Clinical Practice Guidelines May 2014 Table of Contents 1. Purpose ............................................................................................................................................. 1 2. Introduction ...................................................................................................................................... 1 Natural History ................................................................................................................................. 2 Special Considerations ...................................................................................................................... 2 3. Screening ........................................................................................................................................... 3 Screening Questions .......................................................................................................................... 3 Further Screening Methods................................................................................................................ 4 4. Diagnosis ........................................................................................................................................... 4 Depression: Three Levels of Severity ............................................................................................... 4 Clinical Interview and Documentation of Risk Assessment...............................................................
    [Show full text]
  • Drug Class Review on Atypical Antipsychotic Drugs
    Drug Class Review on Atypical Antipsychotic Drugs Final Report April 2006 The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Marian S. McDonagh, PharmD Kim Peterson, MS Susan Carson, MPH Oregon Evidence-based Practice Center Oregon Health & Science University Mark Helfand, MD, MPH, Director Copyright © 2006 by Oregon Health & Science University Portland, Oregon 97201. All rights reserved. Final Report Update 1 Drug Effectiveness Review Project TABLE OF CONTENTS INTRODUCTION............................................................................................................. 5 Scope and Key Questions ......................................................................................................13 METHODS .................................................................................................................... 15 Literature Search ....................................................................................................................15 Study Selection .......................................................................................................................15 Data Abstraction .....................................................................................................................15
    [Show full text]
  • Antipsychotics and the Risk of Sudden Cardiac Death
    ORIGINAL INVESTIGATION Antipsychotics and the Risk of Sudden Cardiac Death Sabine M. J. M. Straus, MD; Gyse`le S. Bleumink, MD; Jeanne P. Dieleman, PhD; Johan van der Lei, MD, PhD; Geert W. ‘t Jong, PhD; J. Herre Kingma, MD, PhD; Miriam C. J. M. Sturkenboom, PhD; Bruno H. C. Stricker, PhD Background: Antipsychotics have been associated with Results: The study population comprised 554 cases of prolongation of the corrected QT interval and sudden car- sudden cardiac death. Current use of antipsychotics was diac death. Only a few epidemiological studies have in- associated with a 3-fold increase in risk of sudden car- vestigated this association. We performed a case- diac death. The risk of sudden cardiac death was high- control study to investigate the association between use est among those using butyrophenone antipsychotics, of antipsychotics and sudden cardiac death in a well- those with a defined daily dose equivalent of more than defined community-dwelling population. 0.5 and short-term (Յ90 days) users. The association with current antipsychotic use was higher for witnessed cases Methods: We performed a population-based case-control (n=334) than for unwitnessed cases. study in the Integrated Primary Care Information (IPCI) project, a longitudinal observational database with com- Conclusions: Current use of antipsychotics in a gen- plete medical records from 150 general practitioners. All eral population is associated with an increased risk of sud- instances of death between January 1, 1995, and April 1, den cardiac death, even at a low dose and for indica- 2001, were reviewed. Sudden cardiac death was classified tions other than schizophrenia.
    [Show full text]
  • Data Sheet SURMONTIL Trimipramine (As Maleate) 25 Mg Tablets and 50 Mg Capsules
    Data Sheet SURMONTIL trimipramine (as maleate) 25 mg tablets and 50 mg capsules Presentation SURMONTIL tablets are compression coated, white or cream, circular, biconvex, containing the equivalent of 25mg trimipramine (as maleate) with a diameter of about 8.0mm. The face is indented with the name and strength, reverse plain. SURMONTIL capsules are opaque white with opaque green cap, printed SU50, each containing the equivalent of 50mg trimipramine (as maleate). Uses Actions SURMONTIL has a potent anti-depressant action similar to that of other tricyclic anti-depressants. The mechanism of action is not fully understood but it is thought to be via inhibition of neuronal re- uptake of noradrenalin, thereby increasing availability. SURMONTIL also possesses a pronounced sedative action. Pharmacokinetics SURMONTIL is readily absorbed after oral administration, reaching a mean peak plasma level after 3 hours. High first pass hepatic clearance results in a mean bioavailability of about 41% of the oral dose, and trimipramine is extensively protein bound in plasma. Elimination half-life is 24 hours. Metabolism is in the liver to its major metabolite, desmethyltrimipramine, which is excreted mainly in the urine. Indications SURMONTIL is indicated in the treatment of depressive illness, especially where sleep disturbance, anxiety or agitation is a presenting symptom. Sleep disturbance is controlled within 24 hours and true anti-depressant action follows within 7-10 days. Dosage and Administration Adults Mild/Moderate Depression in General Practice: The recommended dosage is 50-75 mg orally given two hours before bedtime, the larger dose (75 mg) being preferable for those patients with more marked sleep disturbance.
    [Show full text]
  • Effects of Sympathetic Inhibition on Receptive, Proceptive, and Rejection Behaviors in the Female Rat
    Physiology & Behavior, Vol. 59, No. 3, pp. 537-542, 1996 Copyright © 1996 Elsevier Science Inc. Printed in the USA. All rights reserved 0031-9384/96 $15.00 + .00 ELSEVIER 0031-9384(95)02102-2 Effects of Sympathetic Inhibition on Receptive, Proceptive, and Rejection Behaviors in the Female Rat CINDY M. MESTON, 1 INGRID V. MOE AND BORIS B. GORZALKA Department of Psychology, University of British Columbia, 2136 West Mall, Vancouver, British Columbia, Canada V6T 1Z4 Received 27 September 1994 MESTON, C. M., I. V. MOE AND B. B. GORZALKA. Effects of sympathetic inhibition on receptive, proceptive, and rejection behaviors in the female rat. PHYSIOL BEHAV 59(3) 537-542, 1996.--The present investigation was designed to examine the effects of sympathetic nervous system (SNS) inhibition on sexual behavior in ovariec- tomized, steroid-treated female rats. Clonidine, an alpha2-adrenergic agonist, guanethidine, a postganglionic noradren- ergic blocker, and naphazoline, an alpha2-adrenoreceptor agonist were used to inhibit SNS activity. Intraperitoneal injections of eit:aer 33/zg/ml or 66/xg/ml clonidine significantly decreased receptive (lordosis) and proceptive (ear wiggles) behaviors and significantly increased rejection behaviors (vocalization, kicking, boxing). Either 25 mg/ml or 50 mg/ml guanethidine significantly decreased receptive and proceptive behavior and had no significant effect on rejection behav!iors. Naphazoline significantly inhibited lordosis behavior at either 5 mg/ml or 10 mg/ml doses, significantly inhibited proceptive behavior at 5 mg/ml, and had no significant effect on rejection behaviors. These findings supporc the hypothesis that SNS inhibition decreases sexual activity in the female rat. Lordosis Proceptive behavior Rejection behavior Clonidine Guanethidine Naphazoline Alpha-adrenergic INTRODUCTION as 2 /xg/animal also inhibits lordosis behavior (1).
    [Show full text]
  • How CATIE Brought Us Back to Kansas: a Critical Re-Evaluation of the Concept of Atypical Antipsychotics and Their Place In
    Advances in Psychiatric Treatment (2008), vol. 14, 17–28 doi: 10.1192/apt.bp.107.003970 How CATIE brought us back to Kansas: a critical re-evaluation of the concept of atypical antipsychotics and their place in the treatment of schizophrenia David Cunningham Owens Abstract The subdivision of the class of antipsychotic drugs into two discrete groups – ‘conventional’ (or first generation) and ‘atypical’ (or second generation) – has been adopted as standard, with the latter generally accepted as ‘better’ and widely recommended as automatic first-line choices. However, this perception has been thrown into confusion with the results of large pragmatic trials that failed to identify advantages with the new, more expensive drugs, while identifying worrying tolerability issues. This article explores the origins of ‘atypicality’, its construction on the back of a confusing and weak clinical validator (diminished liability to promote parkinsonism) and how even in relation to the archetypical atypical, clozapine, the uncertain boundaries of drug-induced extrapyramidal dysfunction may be contributing to confusion about ‘efficacy’ and ‘tolerability’. It argues that abandoning atypicality would open up clinical practice to all drugs of a single class of ‘antipsychotics’ and allow for individualised risk/benefit appraisal as a basis for truly tailored treatment recommendations. Sometimes, the best way forward is back – to take This article raises fundamental questions about stock, appraise anew, admit mistakes. This is never our understanding of the clinical pharmacology easy, especially if shadows haunt the way but, if of antipsychotic drugs – so fundamental that (as necessary, is better undertaken sooner than later – numerous publication rejections attest) they were and with honesty.
    [Show full text]
  • (Mibg) Scintigraphy: Procedure Guidelines for Tumour Imaging
    Eur J Nucl Med Mol Imaging (2010) 37:2436–2446 DOI 10.1007/s00259-010-1545-7 GUIDELINES 131I/123I-Metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging Emilio Bombardieri & Francesco Giammarile & Cumali Aktolun & Richard P. Baum & Angelika Bischof Delaloye & Lorenzo Maffioli & Roy Moncayo & Luc Mortelmans & Giovanna Pepe & Sven N. Reske & Maria R. Castellani & Arturo Chiti Published online: 20 July 2010 # EANM 2010 Abstract The aim of this document is to provide general existing procedures for neuroendocrine tumours. The information about mIBG scintigraphy in cancer patients. guidelines should therefore not be taken as exclusive of The guidelines describe the mIBG scintigraphy protocol other nuclear medicine modalities that can be used to obtain currently used in clinical routine, but do not include all comparable results. It is important to remember that the The European Association has written and approved guidelines to promote the use of nuclear medicine procedures with high quality. These general recommendations cannot be applied to all patients in all practice settings. The guidelines should not be deemed inclusive of all proper procedures and exclusive of other procedures reasonably directed to obtaining the same results. The spectrum of patients seen in a specialized practice setting may be different than the spectrum usually seen in a more general setting. The appropriateness of a procedure will depend in part on the prevalence of disease in the patient population. In addition, resources available for patient care may vary greatly from one European country or one medical facility to another. For these reasons, guidelines cannot be rigidly applied. These guidelines summarize the views of the Oncology Committee of the EANM and reflect recommendations for which the EANM cannot be held responsible.
    [Show full text]